Lead Product(s) : PBT2
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PBT2 is a low molecular weight drug candidate, orally bioavailable, crosses the blood-brain barrier, it has demonstrated efficacy in individuals with alzheimer’s disease.
Product Name : PBT2
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : PBT2
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PBT2
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Professor Colin Masters
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the license agreement, Alterity grants the entire rights to the AH patent as well as an exclusive worldwide license to develop and commercialize both AH and PBT2 (acyl hydrazone) in Alzheimer’s disease (AD).
Product Name : PBT2
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : PBT2
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Professor Colin Masters
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ATH434
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Details : ATH434, is an oral agent which inhibits the aggregation of pathological proteins implicated in neurodegeneration disorders like MSA. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve nerve cells by restoring normal iron ba...
Product Name : ATH434
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : ATH434
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable